0 183

Cited 36 times in

Pulmonary marginal zone B-cell lymphoma of MALT type--what is a prognostic factor and which is the optimal treatment, operation, or chemotherapy?: Consortium for Improving Survival of Lymphoma (CISL) study

 Sung Yong Oh  ;  Won Seog Kim  ;  Jin Seok Kim  ;  Seok Jin Kim  ;  Hyuk-Chan Kwon  ;  Dae Ho Lee  ;  Jong Ho Won  ;  In Gyu Hwang  ;  Min Kyoung Kim  ;  Soon Il Lee  ;  Yee Soo Chae  ;  Deok-Hwan Yang  ;  Gyeong-Won Lee  ;  Chul Won Choi  ;  Jinny Park  ;  Cheolwon Suh  ;  Hyo-Jin Kim 
 ANNALS OF HEMATOLOGY, Vol.89(6) : 563-568, 2010 
Journal Title
Issue Date
Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use* ; Diagnostic Techniques, Respiratory System ; Disease Progression ; Female ; Humans ; Lung Neoplasms/diagnosis* ; Lung Neoplasms/mortality ; Lung Neoplasms/therapy* ; Lymphoma, B-Cell, Marginal Zone/diagnosis* ; Lymphoma, B-Cell, Marginal Zone/mortality ; Lymphoma, B-Cell, Marginal Zone/therapy* ; Male ; Middle Aged ; Prognosis ; Retrospective Studies ; Survival Analysis ; Thoracic Surgery, Video-Assisted/utilization ; Tomography, X-Ray Computed ; Treatment Outcome
Pulmonary marginal zone B-cell lymphoma of the MALT type (P-MZL) is a relatively rare form of lymphoma. We conducted a retrospective analysis of the clinical features and treatment outcomes of P-MZL for the evaluation of prognostic factors, and to collect information about the optimal treatment modality for this condition. From 1991 to 2008, a total of 61 patients with biopsy-confirmed P-MZL were retrospectively analyzed. The median age of our subjects was 60 (range, 34-79) years. Twenty-five of the patients (41%) were initially diagnosed without any symptoms. Video-assisted thoracic surgery was utilized for diagnosis in 19 patients (31%). Thirty-eight patients' conditions (62%) involved a single lobe. Lung lesions were bilateral in 15 patients (25%). Eleven patients evidenced synchronous involvement of extra-pulmonary site MZL. Overall, 56 of 61 patients were treated with surgery (n = 22), chemotherapy (n = 28), or radiotherapy (n = 6). Among them, 46 patients achieved complete or partial remission. The median time to progression (TTP) was 5.6 (95% CI, 2.6-8.6) years. Five patients died during follow-up. Extra-pulmonary MZL and LN involvement were shown to be poor prognostic factors for TTP. We noted no differences between the operation group and chemotherapy group in terms of TTP. P-MZL tends to be an indolent disease-characterized by prolonged survival with frequent relapses. This is similar to what is observed with other cases of MALT-type site MZL. In order to conserve lung function and reduce the risks of operation, chemotherapy should be considered as a first-line option for the treatment of P-MZL.
Full Text
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Kim, Jin Seok(김진석) ORCID logo https://orcid.org/0000-0001-8986-8436
사서에게 알리기


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.